BioSante Pharmaceuticals, Inc. Stock Nasdaq
Equities
US09065V2034
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
May. 21 | Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing | MT |
May. 20 | ANI Pharmaceuticals Launches Kionex Suspension | MT |
Financials (USD)
Sales 2024 * | 539M | Sales 2025 * | 577M | Capitalization | 1.26B |
---|---|---|---|---|---|
Net income 2024 * | 33M | Net income 2025 * | 41M | EV / Sales 2024 * | 2.37 x |
Net Debt 2024 * | 20.98M | Net cash position 2025 * | 44.87M | EV / Sales 2025 * | 2.11 x |
P/E ratio 2024 * |
41.4
x | P/E ratio 2025 * |
27
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.44% |
Latest transcript on BioSante Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Nikhil Lalwani
CEO | Chief Executive Officer | 46 | 20-09-07 |
Stephen Carey
DFI | Director of Finance/CFO | 53 | 16-05-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Haughey
BRD | Director/Board Member | 60 | 18-04-30 |
Antonio Pera
BRD | Director/Board Member | 66 | 20-08-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |